News - Vivus, Arena Pharmaceuticals


Popular Filters

1 to 25 of 54 results

Report: Obesity therapy market forecast to reach $8.4 billion by 2022

Report: Obesity therapy market forecast to reach $8.4 billion by 2022


Due to the launches of several novel drugs during the next decade, the obesity therapeutics market will…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNovo NordiskPharmaceuticalVictoza

Eisai to double Belviq sales force by December

Eisai to double Belviq sales force by December


Eisai’s US subsidiary will increase its force for the obesity drug Belviq to around 400 representatives…

Arena PharmaceuticalsBelviqEisaiManagementMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Auxilium gains rights to Vivus ED drug for USA and Canada


Auxilium Pharmaceuticals has signed an agreement with fellow USA-based Vivus providing Auxilium with…

Auxilium PharmaceuticalsLicensingMen's HealthNorth AmericaPharmaceuticalStendraVivus

Vivus obesity drug reduces progression to type 2 diabetes in high-risk overweight patients


New data published on-line in Diabetes Care, today Care demonstrating positive effects of USA-based Vivus’…


Eisai's launch plan for obesity drug Belviq in USA enters consumer phase


The US launch campaign by Japanese drug major Eisai (TYO: 4523) of the weight-loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Market for obesity therapies to reach a value of $2.6 billion in 2019


The global obesity therapeutics market has been forecast to increase at a compound annual growth rate…

GlobalMarkets & MarketingMetabolicsPharmaceuticalQsymiaVivus

Anti-obesity drug market to more than triple by 2019; report


The anti-obesity drug market, which is dominated by off-patent orlistat, Swiss pharma major Roche's (ROG:…

Markets & MarketingMetabolicsorlistatPharmaceuticalQsymiaRocheVivusXenical

Resubmission expected for Orexigen's obesity drug Contrave


US biopharma company Orexigen Therapeutics (Nasdaq: OREX) has announced that the Light Study independent…

Arena PharmaceuticalsBelviqContraveGastro-intestinalsNorth AmericaOrexigen TherapeuticsPharmaceuticalQnexaRegulationVivus

Sanofi to produce avanafil for Vivus


US drugmaker Vivus (Nasdaq: VVUS) says it has entered into a commercial supply agreement with French…

avanafilMen's HealthPharmaceuticalProductionSanofiSpedraVivus

Focus on weight-loss drugs in Latin America


The increasing prevalence of obesity in Brazil and Mexico is encouraging its governments to consider…

Abbott LaboratoriesArena PharmaceuticalsBelviqByettaGastro-intestinalsHealthcareJohnson & JohnsonNovo NordiskPharmaceuticalQsymiaReductilRocheSouth AmericaTopamaxVictozaVivusXenical

Vivus reaches agreement with First Manhattan and appoints new board


A truce has been called between US drugmaker Vivus (Nasdaq: VVUS) and its top investor First Manhattan…

ManagementNorth AmericaPharmaceuticalVivus

Law suit threat for Vivus over battle for shareholders' votes


The battle has heated up between US drugmaker Vivus (Nasdaq: VVUS) and its top investor First Manhattan…

FinancialNorth AmericaPharmaceuticalQsymiaVivus

Vivus offers a compromise to end the proxy contest


US drugmaker Vivus (Nasdaq: VVUS) said on Saturday (July 13) that it had communicated to Sam Colin and…


European approval for Vivus' ED drug Spedra


The European Commission yesterday (June 26) has granted marketing authorization for USA-based Vivus'…

avanafilEuropeMen's HealthPharmaceuticalRegulationReproductiveSpedraVivus

It's official: "obesity is a disease," says AMA


The American Medical Association at its annual meeting this week adopted a policy that recognizes obesity…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Arena/Eisai's Belviq at last to launch in the USA


USA-based Arena Pharmaceuticals (Nasdaq: ARNA) says that its long-awaited weight loss drug Belviq (lorcaserin)…

Arena PharmaceuticalsBelviqEisaiMarkets & MarketingMetabolicsNorth AmericaPharmaceutical

Arena and Eisai finally get DEA scheduling for obesity drug Belviq


The long wait to get obesity drug Belviq (lorcaserin) to the US market, where it was approved by the…

Arena PharmaceuticalsBelviqEisaiMetabolicsNorth AmericaPharmaceuticalRegulation

Arena Pharma pulls EU application for Belviq; posts 1st-qtr results


As part of an update on its activities and first-quarter financial results report, USA-based Arena Pharmaceutical…

Arena PharmaceuticalsBelviqEisaiEuropeFinancialMetabolicsPharmaceuticalRegulation

Vivus rises as FDA eases restrictions on diet pill Qsymia


USA drugmaker Vivus' (Nasdaq: VVUS) shares rose as much as 11% by traded up 5% at $11.69, after the company…

MetabolicsNorth AmericaPharmaceuticalQsymiaRegulationVivus

Vivus announces new discount program for obesity drug Qsymia


US drugmaker Vivus (Nasdaq: VVUS) has announced a new program offering eligible patients a discount on…

Markets & MarketingMetabolicsNorth AmericaPharmaceuticalPricingQsymiaVivus

EMA confirms negative view on Vivus' obesity drug Qsiva after appeal


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dealt a blow to…


1 to 25 of 54 results

Company Spotlight



Back to top